The DEF is the premier industry resource for dermatology NP and PA education, case-based learning, and credible training tools for the practice.
Connect with the Dermatology Education Foundation
Mentorship Opportunities
The DEF awards mentorship grant opportunities on an annual basis. Click below for more information.
DERM2024
The annual DEF Essential Resource Meeting offers AMA PRA Category 1™ credit and
a dermoscopy training course.
DEF Regional Biologic & SMALL MOLECULE NP/PA CME Bootcamps
This regional CME live meeting series offers a unique opportunity to learn more about atopic dermatitis, eczema and psoriasis.
Sign Up
The DEF offers live meetings, conferences and bootcamps as well as online resources to educate and train in all aspects of care for nurse practitioners and physician assistants.
Donate Online
Our mission is to improve dermatology patient outcomes through education and training designed for the practicing NP and PA.
Positive Phase 2 Data Brings New Hope for BCC Patients!
The Phase 2 trial of VP-315, an oncolytic peptide for basal cell carcinoma, shows promising results:
- 51% of treated lesions achieved complete histologic clearance.
- 71% reduction in tumor size ...for lesions with residual tumor.
- Overall tumor size reduction of 86% across all treated lesions.
No dose-limiting toxicities or serious adverse events were reported, with most adverse events being mild to moderate. Verrica plans to present final Phase 2 data at future medical meetings and is preparing for an End-of-Phase 2 meeting with the FDA in early 2025.
Could amino acid deficiencies be the key to unlocking the mystery of chronic itching? 🧬
A new study from the University of Maryland links lower levels of nine specific amino acids to chronic pruritus of unknown origin (CPUO), with these deficiencies correlating to increased itch ...severity. While more studies are needed, these findings offer promising insights that could guide future treatments for this challenging condition.
Mpox Awareness is Declining – Here’s What You Need to Know:
- Only 45% know a vaccine for mpox exists, down from 61% in 2022.
- Just 17% are aware that mpox is less contagious than COVID-19.
- Worry about contracting mpox has dropped, with only 5% ...concerned.
- Awareness that men who have sex with men are at higher risk fell from
63% to 34%.
Stay informed with more insights on this topic by checking out our full blog on the DEF website. #PublicHealth #MpoxAwareness
Join Cynthia Trickett for an Incyte Dermatology-Sponsored Webinar on September 24, 2024 at 8:00 PM ET
- Review the evolving understanding of atopic dermatitis (AD), diagnosis, management, and the patient journey
- Evaluate a treatment option for mild to moderate ...AD
- Understand the indicated patient population for treatment
Register with the link in our bio!
Have you registered for your free access to Reach Rx? Reach Rx - an AI-powered clinical tool that provides rapid and up-to-date information on dermatology drug dosing and interactions, diagnosis, and more - is available free to NPs and PAs through the DEF.
Nemluvio (nemolizumab) by Galderma is now FDA-approved as a pre-filled pen for adults with prurigo nodularis, following its Breakthrough Therapy Designation in 2019. Learn more on the DEF blog! [link in bio] #Dermatology #FDAApproval